Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 4/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960976 | 0.79 | NPC1 (0.45) | NPC1RAB9AMGLLFAAHSMN1; SMN2 | |
| SCHEMBL21961388 | 0.75 | F10 (0.41) | NPC1RAB9ASMN1; SMN2POLBMAOB | |
| SCHEMBL16800423 | 0.72 | NPC1 (0.54) | NPC1RAB9AMGLLFAAHSMN1; SMN2 | |
| SCHEMBL21964587 | 0.71 | HCAR2 (0.38) | — | |
| SCHEMBL21960965 | 0.70 | MAP3K14 (0.35) | SMN1; SMN2POLB | |
| SCHEMBL21964564 | 0.70 | NPC1 (0.51) | NPC1RAB9AMGLLFAAHSMN1; SMN2 | |
| SCHEMBL30206407 | 0.69 | NPC1 (0.53) | NPC1RAB9AMGLLFAAHSMN1; SMN2 | |
| SCHEMBL21960964 | 0.67 | MAP3K14 (0.35) | — | |
| SCHEMBL16797992 | 0.67 | NPC1 (0.53) | NPC1RAB9AMGLLFAAHSMN1; SMN2 | |
| SCHEMBL10874779 | 0.65 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | NPC1 1362/4885RAB9A 3698/4885MGLL 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.